<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="934">
  <stage>Registered</stage>
  <submitdate>9/12/2005</submitdate>
  <approvaldate>16/12/2005</approvaldate>
  <actrnumber>ACTRN12605000795695</actrnumber>
  <trial_identification>
    <studytitle>A Phase II Study of Risk-Adapted IV Melphalan in Patients with AL (Primary systemic) Amyloidosis</studytitle>
    <scientifictitle>Impact of a risk-adapted IV Melphalan schedule on the six month serum free light chain response in patients with AL (Primary systemic) amyloidosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Australasian Leukaemia and Lymphoma Group (ALLG): ALLG MM8</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>AL amyloidosis</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>IV Melphalan will be dosed according to a risk-adapted schedule. Those who can safely receive high-dose IV Melphalan (=Transplant candidates) must have minimal cardiac disease (BNP&lt;300, BP &gt;90, no CCF/arrhythmias, O2 sats &gt;94%, EF &gt;40%), age &lt; 65, ECOG performance status &lt; 2, organs involved &lt; 2 and bilirubin &lt; 30mmol/L). Patients unsuitable for high-dose Melphalan (Non-transplant candidates) will receive intermediate-dose IV Melphalan and dexamethasone.Transplant candidates:Peripheral blood stem cell collection with filgrastim alone (10Âµg/kg)Autologous stem cell transplantation with melphalan (140mg/m2 if CrCl &lt; 50 mls/min or age &gt; 60 yrs or ECOG performance status=2, otherwise 200mg/m2). Non-transplant candidates:Melphalan 20mg/m2 iv + dexamethasone 40mg d1-4 every 4 weeks for 2 cycles beyond free light chain plateau</interventions>
    <comparator>Uncontrolled study- no control</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the proprotion of patients who achieve a 50% reduction serum free lighty chains at 6 months following therapy with intravenous melphalan</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the treatment related mortality as defined by death within 100 days of completion of therapy.</outcome>
      <timepoint>100 days following completion of therapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the duration of serum free light chain response.</outcome>
      <timepoint>time from first achievement of a 50% reduction in the monoclonal light chain until the time of free light chain increase of 50% from nadir and an increase to &gt; 100mg/L</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the organ response rates as defined by disease specific criteria.</outcome>
      <timepoint>2 years following start of therapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine overall survival.</outcome>
      <timepoint>Study closeout date</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Confirmed diagnosis of AL amyloidosis (must have biopsy-proven amyloidosis and identification of a monoclonal light chain in the serum, urine or in a bone marrow where a monoclonal light chain is identified by immunohistochemical staining or flow cytometry). Positive immunohistochemistry of amyloid deposits or exclusion of hereditary mutations is required if there is uncertainty as to the type of amyloid. 2. Evidence of cardiac, renal, liver or neurologic involvement or other symptomatic organ involvement (asymptomatic gastrointestinal or marrow involvement alone are not indications for study inclusion). 3. ECOG performance status 0 to 3 inclusive. 4. Written informed consent prior to study registration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Clinically overt multiple myeloma with &gt; 30% plasma cells in the bone marrow or the presence of lytic bone lesions or hypercalaemia2. B-cell lymphoproliferative disease3. Prior intravenous melphalan4. Therapy to reduce plasma cell dyscrasia within the previous four weeksNote: Prior stem cell mobilisation with G-CSF is not an exclusion criteria5. Absolute neutrophil count &lt; 1.5 x 109 /L and platelet count &lt; 100 x 109/L6. Concurrent or previous malignancy except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix or other solid tumors treated for cure with no evidence of disease for at least 2 years7. Known HIV positivity8. Likely inability of the patient to comply with treatment assessments9. Pregnancy and lactation. Adults of reproductive potential must agree to use an effective method of birth control during treatment and for at least 3 months thereafter.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>7/01/2006</anticipatedstartdate>
    <actualstartdate>13/06/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate>17/04/2009</actualenddate>
    <samplesize>28</samplesize>
    <actualsamplesize>21</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/12/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Leukaemia and Lymphoma Group</primarysponsorname>
    <primarysponsoraddress>Level 2/ 10 St Andrews Place
East Melbourne, Australia, 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Leukaemia Foundation of Queensland</fundingname>
      <fundingaddress>P O Box 6577, Cairns, QLD 4870</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Amgen Australia</fundingname>
      <fundingaddress>Amgen Australia Pty Ltd
Level 1, 801 Glenferrie Road
Hawthorn VIC 3122</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication>Mollee P, Tiley C, Cunningham I, Moore J, Prince HM, Cannell P, Gibbons S, Tate J, Paul S, Mar Fan H, Gill DS. A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. British journal of haematology. 2012;157(6):766-769</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Woolloongabba, QLD 4102</ethicaddress>
      <ethicapprovaldate>31/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Peter Mollee</name>
      <address>Haematology Department
Princess Alexandra Hospital
Ipswich Road
Woollongabba QLD 4102</address>
      <phone>+61 7 32406739</phone>
      <fax>+61 7 32407042</fax>
      <email>peter.mollee@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof. Sanjoy Paul</name>
      <address>Queensland Clinical Trials &amp; Biostatistics Centre
Princess Alexandra Hospital, Ipswich Road, Woolloongabba QLD 4102</address>
      <phone>+61 7 3176 5809</phone>
      <fax />
      <email>s.paul@sph.uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>